Medigene Etomoxir ein Witz!!!! - 500 Beiträge pro Seite

[doyourhomework]

Etomoxir:

Der größte Hoffnungsträger in Medigenes Produktpipeline?

Aber,was macht der Mann,welcher die Patente an Etomoxir hält, und den Wirkstoff am besten kennt,der saftige Lizenzgebühren aus den Kassen von Medigene erwarten könnte?
Er sitzt da und reibt sich die Hände,weil Etomoxir ein voller Erfolg wird?
Nein,er verscheuert seine Rechte im Internet:

6500,00Euro gegen 0,2% Profit,nach meiner Rechnung,3250000 Euro für alles.Darin sind auch noch die zukünftigen Einahmen aus weiteren Wirkstoffen enthalten.

Der Mann sieht die Sache etwas nüchterner,als die meisten
Medigene Aktionäre,denn die bezahlen ca. 1000000000Euro Marketcap..

Übrigens,obenstehendes ist meine eigene persönliche Meinung

WELCOME TO DR. WOLF RESEARCH PHARMACEUTICALS


--------------------------------------------------------------------------------

ABOUT US



THE COMPANY

PRESIDENT AND CHIEF EXECUTIVE OFFICER

INTELLECTUAL PROPERTY

PRODUCTS AND TECHNOLOGY


For sale


For license


For investment






THE COMPANY

DR. WOLF and Co. (the "Company") is engaged in the development of Etomoxir and backups - drugs in development - for the treatment of various metabolic diseases. The Company was founded in 1992 around three key assets:

(1) a senior biochemist with broad knowledge of carbohydrate and lipid metabolism,
(2) a major innovative and well documented drug development (Etomoxir) until clinical phase II, and
(3) world-wide exclusive patent rights, see

The Company`s strategy has two platforms:

(1) discover new therapeutic targets for Etomoxir,
(2) out-licence the patent rights for product development and commercialization, and
(3) sell various substances for experimental use.

The Company`s most advanced product in development is Etomoxir. In July 1999 the Company completed an exclusive licence agreement with the MediGene AG company in Planegg/Martinsried, Germany for the further development of Etomoxir for the treatment of heart insufficiency (http://www.medigene.de).



PRESIDENT AND CHIEF EXECUTIVE OFFICER


Dr. Horst P.O. Wolf (58) is president and chief executive officer. He has 25 years of experience in pharmaceutical research & development. His career has included experience in both university (Leipzig, Faculty of Veterinary Medicine, Department of Biochemistry as well as Clinical Laboratory in the Children`s Hospital) and pharmaceutical company (Byk Gulden Pharmaceuticals GmbH, Constance, Germany). Dr. Wolf was graduated (Ph.D.) with magna cum laude in 1970 in biochemistry from the University of Leipzig, Germany.





INTELLECTUAL PROPERTY

Four patents are owned by Dr. Wolf. The patent protection for Etomoxir covers:

(1) substance protection and the indication protection for treatment of type 2 diabetes,
(2) indication protection for treatment of hyperlipidemia, arteriosclerosis and coronary heart diseases, and
(3) indication protection for treatment of heart insufficiency.


The patent protection for the backups covers:

(1) various substances and
(2) indication protection for treatment of insulin resistance and type 2 diabetes.



TIME PERIOD OF THE PROTECTION:

The remaining period for the Etomoxir substance patent along with the diabetic indication is short and ends in year 2001/2. However, this handicap is surmounted by the new backups filed for patent protection in 1997 for the same indication.

The remaining period for the second indication patent (hyperlipidemia, arteriosclerosis, and coronary heart diseases) lasts until 2006/7.

The indication protection for heart insufficiency lasts until 2014/15 and the protection period for the backups lasts until 2017/18. It must be emphasized that the indication patents are just as comprehensive as the substance patent, if nobody develops Etomoxir as an anti-diabetic drug as it currently seems to be.



PATENTS:


1. Phen(alk)oxy-substituted oxirane carboxylic acid, process of their preparation, their use and medicaments containing these compounds

Country Patent number Filing date Approval date Date of expiry

Belgium 0 046 590 24.08.1981 22.05.1985 24.08.2001
Denmark 1 838/82 24.08.1981 04.08.1994 31.08.2001
Germany P 3 170 680.8-08 24.08.1981 22.05.1985 31.08.2001
France 0 046 590 24.08.1981 22.05.1985 24.08.2001
Israel 63 627 24.08.1981 30.04.1985 20.08.2001
Canada 1 167 050 24.08.1981 08.05.1984 08.05.2001
Sweden 81 106 556.4 24.08.1981 22.05.1985 31.08.2001
Switzerland 0 046 590 24.08.1981 22.05.1985 31.08.2001
USA 4 337 267 03.04.1981 29.06.1982 03.04.2001



2. Use of oxirane carboxylic acids for treatment of hyperlipidemia

Country Patent number Filing date Approval date Date of expiry

Belgium 231 367 29.07.1986 29.07.1986 29.07.2006
Germany P 3 680 507.6-08 29.07.1986 24.07.1991 29.07.2006
France 231 367 29.07.1986 29.07.1986 29.07.2006
Great Britain 231 367 29.07.1986 24.07.1991 29.07.2006
Italy 231 367 29.07.1986 24.07.1991 29.07.2006
Japan 2.556.496 29.07.1986 05.09.1996 29.07.2006
Luxembourg 231 367 29.07.1986 29.07.1986 29.07.2006
Netherlands 231 367 29.07.1986 24.07.1991 29.07.2006
Austria E 65 398 29.07.1986 24.07.1991 29.07.2006
Sweden 86 905 205.6 29.07.1986 24.07.1991 29.07.2006
Switzerland 231 367 29.07.1986 24.07.1991 29.07.2006
USA 4 946 866 29.07.1986 07.08.1990 07.08.2007



3. Etomoxir as drug for treating heart insufficiency

Country Filing number Filing date Approval date Date of expiry

Belgium 95901328.5 12.01.1993 ................. 24.11.2014
Denmark 95901328.5 12.01.1993 ................. 24.11.2014
Germany 95901328.5 12.01.1993 ................. 24.11.2014
France 95901328.5 12.01.1993 ................. 24.11.2014
UK 95901328.5 12.01.1993 ................. 24.11.2014
Greece 95901328.5 12.01.1993 ................. 24.11.2014
Israel 95901328.5 12.01.1993 ................. 24.11.2014
Italy 95901328.5 12.01.1993 ................. 24.11.2014
Canada 95901328.5 12.01.1993 ................. 24.11.2014
Luxembourg 95901328.5 12.01.1993 ................. 24.11.2014
Monaco 95901328.5 12.01.1993 ................. 24.11.2014
Netherlands 95901328.5 12.01.1993 ................. 24.11.2014
Austria 95901328.5 12.01.1993 ................. 24.11.2014
Portugal 95901328.5 12.01.1993 ................. 24.11.2014
Sweden 95901328.5 12.01.1993 ................. 24.11.2014
Switzerland 95901328.5 12.01.1993 ................. 24.11.2014
Spain 95901328.5 12.01.1993 ................. 24.11.2014
USA 95901328.5 12.01.1993 ................. 14.04.2015



4. New oxirane carboxylic acids for treatment of diabetes type 2 and other states with insulin resistance

Country Patent number Filing date Approval date Date of expiry

Germany D 197 05 718.7 02.04.1997
World-wide PCT/EP98/00611 02.05.1998



PRODUCTS AND TECHNOLOGY

PRODUCTS FOR SALE: The following substances can be delivered for experimental use only

No Substance Quantity US $ / Euro

1 rac-Etomoxir, ethylester unsoluble in water, mol wt 326.8, purity > 99% 1 gram 350.00

2 rac-Etomoxir, sodium salt, x 2H20, water soluble, mol wt 356.8, purity > 99% 1 gram 430.00

3 (R)-(+)-Etomoxir, ethylester unsoluble in water, mol wt 326.8, purity > 99% 1 gram 378.00


4 (R)-(+)-Etomoxir, sodium salt x 1 H20, water soluble, mol wt 338.8, purity > 99% 1 gram 430.00

5 (S)-(-)-Etomoxir, potassium salt water soluble, mol wt 336.9, purity > 98% 1 gram 715.00

6 DNP-Etomoxir, sodium salt x 1 H20, water soluble, mol wt 394.3, purity > 98% 1 gram 675.00

7 Wet gelatine capsules filled with (R)-(+)-Etomoxir, ethylester 10, 20, 40, and 80 mg, respectively 1 gram 420.00

8 Coenzyme A - derivatives of the above compounds 1 gram on request


Discounts: 10% > / = 5 gram
20% > / = 10 gram
30% > / = 20 gram
50% > / = 50 gram



TECHNOLOGY FOR LICENSE:

The following patent rights are available for license.

1. Second indication patent (hyperlipidemia, coronary heart diseases, and arteriosclerosis) for Etomoxir (see patents 2.).
Countries: BE, D, F, UK, I, JP, NL, S, CH, USA

2. Substance patent and indication patent (insulin resistance, diabetes type 2) for new oxirane carboxylic acid derivatives (CPT 1 inhibitors, backups to Etomoxir) (see patents 4.).
Countries: world-wide filed in 1998.



FOR INVESTMENT

The Company offers silent partnership investment. This form of venture capital investment may be a very profitable form for private or institutional investors.

Price of "shares":
Euro 6.500,00 for 0,2 % of the Company´s profit

For more detailed information, please contact the CEO.

QUELLE:www.etomoxir.com

Oder, wie beurteilt ihr das?

[doyourhomework]

Kopf in den Sand stecken und Tatsachen ignorieren,klasse Taktik.

Hier noch ein paar Infos:


Genauso,wie die DR. WOLF and Co, versucht seine Firmenanteile zu verklopfen,werden es auch die Venturecapitalgeber und Altaktionäre machen.
Die warten nicht bis 2003 oder 2007, auf Fakten,sondern machen Kasse.
Wer deren AKTIEN kaufen soll ist fraglich, denn Institutionen, werden
nicht zugreifen, bis Medigene seine Patentstreitigkeiten mit positiven
Ausgang abgeschlossen hat.

doyourhomework

[momi]

Patentstreitigkeiten?

[Bruder Leichtsinn]

Gehört in die Rubrik Müllpost.

[Taxameter]

Schon beunruhigend das Anfang November was zum Patentstreit kommen sollte und der Kurs nun fällt!
Was kommt da wohl?

[a.head]

Dann schau doch mal wer den Freefloat besitzt, fast ausschliesslich Institutionelle.


mfg a.head